Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Research Article

miRNA-99a-5p在调节肝细胞癌细胞功能中的作用:生物信息学分析和体外测定

卷 23, 期 6, 2023

发表于: 02 March, 2023

页: [461 - 470] 页: 10

弟呕挨: 10.2174/1568009623666230202155440

价格: $65

Open Access Journals Promotions 2
摘要

目的:本研究旨在探讨miRNAs在肝胆肿瘤中的生物学功能,作为靶向治疗研究的重点。 背景:肝胆肿瘤是全世界癌症相关死亡的主要原因之一。许多 microRNA (miRNA) 在肿瘤进展中起着重要的调节作用。我们的研究旨在探索来自不同肝胆肿瘤数据集的一些具有生物学功能的 miRNA,用于疾病诊断或治疗。 目标:在本研究中,我们试图从 GEO 数据库中筛选出不同肿瘤数据集中差异表达的 miRNA。 方法:在本研究中,我们首先对不同的 GEO 数据集进行分析。走交集后,最初的范围仅限于几个差异RNA。然后,结合现有的Kaplan-Meier生存分析和文献研究结果,最终确定了候选分子进行研究。此外,基于Cancermirnome在线工具对候选分子进行生物学特性分析,包括在肿瘤中的表达水平、KEGG和GO分析、ROC分析、靶基因预测等。此外,通过体外实验验证了候选分子对肝癌生物学功能的影响。 结果:生物信息学初步分析表明,16个差异表达的miRNA可能在HCC或ICC中发挥重要作用。最终,我们将 miRNA-99a-5p 确定为唯一要研究的分子。结果显示,miRNA-99a-5p在多种肿瘤中异常表达,而在肝癌中,其在肿瘤组织中的表达水平明显低于正常组织。然后,KEGG 和 GO 分析发现它在多个通路中起作用。同时,ROC 分析发现它在 HCC 中显示出巨大的预后预测潜力,我们还预测 RUNDC3B 是它最有可能结合的靶标。最后,过表达和敲低的实验结果证实miRNA-99a-5p可以抑制HCC细胞增殖,这也提示它可能是HCC的重要抑癌因子。 结论:MiRNA-99a-5p与HCC进展呈负相关,可作为HCC的新治疗靶点。

关键词: MiRNA-99a-5p,预后,增殖,肝癌,靶向治疗,肝胆。

图形摘要
[1]
Massarweh, N.N.; El-Serag, H.B. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Contr., 2017, 24(3)1073274817729245
[http://dx.doi.org/10.1177/1073274817729245] [PMID: 28975830]
[2]
Llovet, J.M.; Pinyol, R.; Kelley, R.K.; El-Khoueiry, A.; Reeves, H.L.; Wang, X.W.; Gores, G.J.; Villanueva, A. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat. Can., 2022, 3(4), 386-401.
[http://dx.doi.org/10.1038/s43018-022-00357-2] [PMID: 35484418]
[3]
Hewitt, D.B.; Brown, Z.J.; Pawlik, T.M. Surgical management of intrahepatic cholangiocarcinoma. Expert Rev. Anticancer Ther., 2022, 22(1), 27-38.
[http://dx.doi.org/10.1080/14737140.2022.1999809] [PMID: 34730474]
[4]
Xu, L.; Huang, X.; Lou, Y.; Xie, W.; Zhao, H. Regulation of apoptosis, autophagy and ferroptosis by non coding RNAs in metastatic non small cell lung cancer. Review Exp. Ther. Med., 2022, 23(5), 352.
[http://dx.doi.org/10.3892/etm.2022.11279] [PMID: 35493430]
[5]
Roy, R.K.; Yadav, R.; Sharma, U.; Wasson, M.K.; Sharma, A.; Tanwar, P.; Jain, A.; Prakash, H. Impact of noncoding RNAS on cancer directed immune therapies: Now then and forever. Int. J. Cancer, 2022, 151(7), 981-992.
[http://dx.doi.org/10.1002/ijc.34060] [PMID: 35489027]
[6]
Zhou, Z.; Wang, Z.; Gao, J.; Lin, Z.; Wang, Y.; Shan, P.; Li, M.; Zhou, T.; Li, P. Noncoding RNA-mediated macrophage and cancer cell crosstalk in hepatocellular carcinoma. Mol. Ther. Oncolytics, 2022, 25, 98-120.
[http://dx.doi.org/10.1016/j.omto.2022.03.002] [PMID: 35506150]
[7]
Li, Z.; Shen, J.; Chan, M.T.V.; Wu, W.K.K. The role of microRNAs in intrahepatic cholangiocarcinoma. J. Cell. Mol. Med., 2017, 21(1), 177-184.
[http://dx.doi.org/10.1111/jcmm.12951] [PMID: 27619971]
[8]
Lee, Y.S.; Dutta, A. MicroRNAs in Cancer. Annu. Rev. Pathol., 2009, 4(1), 199-227.
[http://dx.doi.org/10.1146/annurev.pathol.4.110807.092222] [PMID: 18817506]
[9]
Tiwari, A.; Mukherjee, B.; Dixit, M. MicroRNA key to angiogenesis regulation: MiRNA biology and therapy. Curr. Cancer Drug Targets, 2018, 18(3), 266-277.
[http://dx.doi.org/10.2174/1568009617666170630142725] [PMID: 28669338]
[10]
Mishra, S.; Yadav, T.; Rani, V. Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit. Rev. Oncol. Hematol., 2016, 98, 12-23.
[http://dx.doi.org/10.1016/j.critrevonc.2015.10.003] [PMID: 26481951]
[11]
Rupaimoole, R.; Slack, F.J. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov., 2017, 16(3), 203-222.
[http://dx.doi.org/10.1038/nrd.2016.246] [PMID: 28209991]
[12]
Sun, Y.; Chen, G.; He, J.; Huang, Z.G.; Li, S.H.; Yang, Y.P.; Zhong, L.Y.; Ji, S.F.; Huang, Y.; Chen, X.H.; He, M.L.; Wu, H. Clinical significance and potential molecular mechanism of miRNA-222-3p in metastatic prostate cancer. Bioengineered, 2021, 12(1), 325-340.
[http://dx.doi.org/10.1080/21655979.2020.1867405] [PMID: 33356818]
[13]
Liu, G.; Lei, Y.; Luo, S.; Huang, Z.; Chen, C.; Wang, K.; Yang, P.; Huang, X. MicroRNA expression profile and identification of novel microRNA biomarkers for metabolic syndrome. Bioengineered, 2021, 12(1), 3864-3872.
[http://dx.doi.org/10.1080/21655979.2021.1952817] [PMID: 34269146]
[14]
Li, R.; Qu, H.; Wang, S.; Chater, J.M.; Wang, X.; Cui, Y.; Yu, L.; Zhou, R.; Jia, Q.; Traband, R.; Wang, M.; Xie, W.; Yuan, D.; Zhu, J.; Zhong, W.D.; Jia, Z. CancerMIRNome: An interactive analysis and visualization database for miRNome profiles of human cancer. Nucleic Acids Res., 2022, 50(D1), D1139-D1146.
[http://dx.doi.org/10.1093/nar/gkab784] [PMID: 34500460]
[15]
Hua, S.; Quan, Y.; Zhan, M.; Liao, H.; Li, Y.; Lu, L. miR-125b-5p inhibits cell proliferation, migration, and invasion in hepatocellular carcinoma via targeting TXNRD1. Cancer Cell Int., 2019, 19(1), 203.
[http://dx.doi.org/10.1186/s12935-019-0919-6] [PMID: 31384178]
[16]
Fang, F.; Chang, R.; Yu, L.; Lei, X.; Xiao, S.; Yang, H.; Yang, L.Y. MicroRNA-188-5p suppresses tumor cell proliferation and metastasis by directly targeting FGF5 in hepatocellular carcinoma. J. Hepatol., 2015, 63(4), 874-885.
[http://dx.doi.org/10.1016/j.jhep.2015.05.008] [PMID: 25998163]
[17]
Chen, L.; Heikkinen, L.; Wang, C.; Yang, Y.; Sun, H.; Wong, G. Trends in the development of miRNA bioinformatics tools. Brief. Bioinform., 2019, 20(5), 1836-1852.
[http://dx.doi.org/10.1093/bib/bby054] [PMID: 29982332]
[18]
Lu, T.X.; Rothenberg, M.E. MicroRNA. J. Allergy Clin. Immunol., 2018, 141(4), 1202-1207.
[http://dx.doi.org/10.1016/j.jaci.2017.08.034] [PMID: 29074454]
[19]
Hill, M.; Tran, N. miRNA interplay: Mechanisms and consequences in cancer. Dis. Model. Mech., 2021, 14(4)dmm047662
[http://dx.doi.org/10.1242/dmm.047662] [PMID: 33973623]
[20]
Shi, Y.; Zhang, D.D.; Liu, J.B.; Yang, X.L.; Xin, R.; Jia, C.Y.; Wang, H.M.; Lu, G.X.; Wang, P.Y.; Liu, Y.; Li, Z.J.; Deng, J.; Lin, Q.L.; Ma, L.; Feng, S.S.; Chen, X.Q.; Zheng, X.M.; Zhou, Y.F.; Hu, Y.J.; Yin, H.Q.; Tian, L.L.; Gu, L.P.; Lv, Z.W.; Yu, F.; Li, W.; Ma, Y.S.; Da, F. Comprehensive analysis to identify DLEU2L/TAOK1 axis as a prognostic biomarker in hepatocellular carcinoma. Mol. Ther. Nucleic Acids, 2021, 23, 702-718.
[http://dx.doi.org/10.1016/j.omtn.2020.12.016] [PMID: 33575116]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy